European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Center for Epidemiology and Health Research, Germany.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Juergen Dinger, MD, PhD, Center for Epidemiology and Health Research, Germany
ClinicalTrials.gov Identifier:
NCT00214903
First received: September 19, 2005
Last updated: October 25, 2011
Last verified: October 2011
  Purpose

The objective of the active surveillance study is to compare incidence rates of serious adverse events in users of all types of newly prescribed oral HRT products. The primary focus is the assessment of pertinent cardiovascular outcomes (such as venous and arterial thromboembolism) in new HRT users over a study period of 3 to 6 years. Also, all other serious adverse events will be analyzed.


Condition Phase
Postmenopause
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: European Active Surveillance Study of Women Taking HRT

Further study details as provided by Center for Epidemiology and Health Research, Germany:

Primary Outcome Measures:
  • Venous and arterial thromboembolism [ Time Frame: within 6 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30000
Study Start Date: November 2004
Estimated Study Completion Date: December 2009
Groups/Cohorts
1
Users of oral HRT containing drospirenone
2
Users of oral HRT containing other progestagens

Detailed Description:

The safety of a novel drug product containing a new chemical entity should be assessed in an extensive post marketing safety surveillance program. It is also prudent to assess both, the safety outcomes that relate specifically to the targeted population, as well as those that could potentially be related to the special pharmacological characteristics of the novel drug product. Differentiating between the inherent background population risk and a potential incremental risk due to treatment is often challenging. Active safety surveillance using valid epidemiological study designs has been proven to be a pertinent and reliable method to approach this endeavour.

The primary objective of the study, the European Active Surveillance Study of Women taking HRT (EURAS-HRT), is to compare incidence rates of serious adverse events in users of all types of newly prescribed oral HRT products. This active surveillance study will assess pertinent cardiovascular outcomes in new HRT users over a study period of 3 to 6 years. Also, all other serious adverse events will be reported.

The new drug product under surveillance in the EURAS - HRT study is Angeliq®, which contains the novel synthetic progestagen drospirenone (DRSP) combined with estradiol. In addition, all other oral combined HRT products with a novel progestagen that will be newly marketed during the study period could be included in this study. These new HRT products will be compared with established HRT products.

As estrogen/progestagen combinations increase the risk for thromboembolism, all new drug products that contain a novel estrogen or progestagen should be investigated for their influence on venous and arterial thromboembolic events rates. A large, prospective, controlled cohort study of OC users (EURAS OC study), which compared DRSP-containing OC users with other OC users, demonstrated that DRSP is not associated with an increased incidence for any of the above-mentioned adverse events in OC users. However, because OC users are two to three decades younger than the typical HRT user the results of the OC study can only partially be extrapolated to older age groups.

The combined cohort will include at least 30,000 women recruited in several European countries. At least 90,000 years of observation are expected from the field work which will end around 2010.

The participating women will complete a baseline survey using a self-administered questionnaire to describe the baseline risk. After 6 months, 12 months, and then on an annual basis, they will fill out a questionnaire in which they record complaints and events during the use of the prescribed HRTs. All adverse outcomes (including cancer) occurring during the observational period will be evaluated additionally. Reported serious adverse events will be validated and analyzed.

Based on experience obtained in previous HRT studies, complex sources of bias and confounding are expected. Multivariate methods will therefore be used to adjust for confounding. This study will emphasize absolute as opposed to relative risk estimates.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Women aged 40 or more years using HRT

Criteria

Inclusion Criteria:

  • All women aged 40 or more years who started or switched to an oral HRT at the time of inclusion in the study

Exclusion Criteria:

  • Women who do not consent to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00214903

Locations
Germany
Center for Epidemiology and Health Research
Berlin, Germany, 10115
Sponsors and Collaborators
Center for Epidemiology and Health Research, Germany
Bayer
Investigators
Principal Investigator: Juergen C Dinger, MD, PhD ZEG, Invalidenstrasse 115, 10115 Berlin, Germany
  More Information

No publications provided

Responsible Party: Juergen Dinger, MD, PhD, Principal Investigator, Center for Epidemiology and Health Research, Germany
ClinicalTrials.gov Identifier: NCT00214903     History of Changes
Other Study ID Numbers: ZEG 2000_3
Study First Received: September 19, 2005
Last Updated: October 25, 2011
Health Authority: Netherlands: Medicines Evaluation Board (MEB)

Keywords provided by Center for Epidemiology and Health Research, Germany:
Postmenopause
HRT

ClinicalTrials.gov processed this record on October 23, 2014